CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 809,102	$ 648,719
Marketable securities	236,121	251,761
Accounts receivable - trade, net	1,152,489	739,379
Accounts receivable from Sanofi	153,152	111,510
Accounts receivable from Bayer HealthCare	162,152	125,483
Inventories	238,578	128,861
Prepaid expenses and other current assets	163,501	79,046
Total current assets	2,915,095	2,084,759
Marketable securities	632,162	460,154
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	1,594,120	974,309
Deferred tax assets	461,945	315,416
Other assets	5,810	3,034
Total assets	5,609,132	3,837,672
Current liabilities:
Accounts payable and accrued expenses	644,112	483,489
Deferred revenue from Sanofi, current portion	101,573	15,927
Deferred revenue - other, current portion	51,914	58,098
Other current liabilities	13,563	97,146
Total current liabilities	811,162	654,660
Deferred revenue from Sanofi	582,664	62,819
Deferred revenue - other	82,015	72,430
Facility lease obligations	362,919	310,938
Convertible senior notes	0	146,773
Other long term liabilities	115,535	39,801
Total liabilities	$ 1,954,295	$ 1,287,421
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred Stock	$ 0	$ 0
Additional paid-in capital	3,099,526	2,450,782
Retained earnings	852,700	216,644
Accumulated other comprehensive income	8,572	52,251
Treasury Stock	(306,069)	(169,530)
Total stockholders' equity	3,654,837	2,550,251
Total liabilities and stockholders' equity	5,609,132	3,837,672
Class A Stock
Stockholders' equity:
Common stock	2	2
Total stockholders' equity	2	2
Common Stock
Stockholders' equity:
Common stock	106	102
Total stockholders' equity	$ 106	$ 102